The study included 184 patients with type 2 diabetes referred to the specialist clinic or admitted in the sections of Al-Assad University Hospital in Damascus during the years 2012-2013.
The patients were divided into three groups: Group A: a group of patients with diabetes is not treated with Metformin, 72 patients (39,1%). Group B: a group of patients with diabetes is treated with Metformin for more than 18 months, 72 patients (39,1%). Group C: a group of patients with diabetes is treated with Metformin for less than 6 months, 40 patients (21,8%). This study showed that 43,5% of the patients have Vit B12 deficiency: 32,6% of patients with diabetes treated with Metformin compared with 10,9% non treated with Metformin. The patients who were treated with Metformin (112 patients) were divided by dose intake and then depending on the duration of treatment into two groups for each category and shown an inverse correlation between duration and dose of therapy with metformin and levels of Vit B12.
We also found that despite the increased risk of Vit B12 deficiency in patients with diabetes treated with Metformin but this was not associated with the occurrence of symptoms such as megaloplastic anemia and neurological symptoms.
to investigate the effect of Pelargonium odoratissimum ethanolic extract (POEE)
in alloxan-induced diabetic rats.
This study aims to compare between two globally approved strategies to manage diabetes type II in Syria, by comparing their effectiveness in patients with diabetes type II who are treated in the national program of diabetes Clinics in Damascus and in
vestigate their glucose control. The first strategy includes glibenclamide as a monotherapy and the second includes a combination of glibenclamide and metformin.
يستخدم الميتفورمين كخط علاجي أول لضبط داء السكري من النمط الثاني غير المضبوطين بالحميه خاصة عند المرضى زائدي الوزن
